Search results for: Moemen A. Heiba

Authors: Inas E. Darwish, Alia M. Arab, Tarek A. Azeim, Teshreen M. Zeitoun, Wafaa A. Hewedy, Moemen A. Heiba, Iman S. Emara

Abstract:

Inflammatory bowel disease (IBD) is a chronic relapsing-remitting condition that afflicts millions of people throughout the world and impairs their daily functions and quality of life. Treatment of IBD depends largely on 5-aminosalicylic acid (5- ASA) and corticosteroids. The present study aimed to clarify the effects of 5-aminosalicylic acid, budesonide and currcumin on 90 male albino rats against trinitrobenzene sulfonic acid (TNB) induced colitis. TNB was injected intrarectally to 50 rats. The other 40 rats served as control groups. Both 5-ASA (in a dose of 120 mg/kg) and budesonide (in a dose of 0.1 mg/kg) were administered daily for one week whereas currcumin was injected intraperitonially (in a dose of 30 mg/kg daily) for 14 days after injection of either TNB in the colitis rats (group B) or saline in control groups (group A). The study included estimation of macroscopic score index, histological examination of H&E stained sections of the colonic tissue, biochemical estimation of myeloperoxidase (MPO), nitric oxide (NO), and caspase-3 levels, in addition to studying the effect of tested drugs on colonic motility. It was found that budesonide and curcumin improved mucosal healing, reduced both NO production and caspase- 3 level. They had the best impact on the disturbed colonic motility in TNBS-model of colitis.

Keywords: Colitis, curcumin, nitric oxide.

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1630

Authors: Lubna M. Zakaryia Mahmoud, Mohammed A. Dawood, Doaa A. Heiba

Abstract:

A prospective double-blind placebo controlled trial carried out on 60 children known to be asthmatic who presented to the emergency department at Alexandria University of Children’s Hospital at El-Shatby with acute asthma exacerbations to assess the efficacy of adding inhaled magnesium sulfate to β-agonist, compared with β-agonist in saline, in the management of acute asthma exacerbations in children. The participants in the study were divided in two groups; Group A (study group) received inhaled salbutamol solution (0.15 ml/kg) plus isotonic magnesium sulfate 2 ml in a nebulizer chamber. Group B (control group): received nebulized salbutamol solution (0.15 ml/kg) diluted with placebo (2 ml normal saline). Both groups received inhaled solution every 20 minutes that was repeated for three doses. They were evaluated using the Pediatric Asthma Severity Score (PASS), oxygen saturation using portable pulse oximetry and peak expiratory flow rate using a portable peak expiratory flow meter at initially recorded as zero-minute assessment and every 20 minutes from the end of each nebulization (nebulization lasts 5-10 minutes) recorded as 20, 40 and 60-minute assessments. Regarding PASS, comparison showed non-significant difference with p-value 0.463, 0.472, 0.0766 at 20, 40 and 60 minutes. Regarding oxygen saturation, improvement was more significant towards group A starting from 40 min with significant p-value=0.000. At 60 min p-value=0.000. Although mean PEFR significantly improved from zero-min in both groups; however, improvement was more significant in group A with significant p-value = 0.015, 0.001, 0.001 at 20 min, 40 min and 60 min, respectively. The conclusion this study suggests is that inhaled magnesium sulfate is an efficient add on drug to standard β- agonist inhalation used in the treatment of moderate to severe asthma exacerbations.

Keywords: Nebulized, magnesium sulfate, acute asthma, pediatric.

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1609